Niedzielska Ewa, Smaga Irena, Gawlik Maciej, Moniczewski Andrzej, Stankowicz Piotr, Pera Joanna, Filip Małgorzata
Department of Toxicology, Chair of Toxicology, Faculty of Pharmacy, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
Department of Neurology, Faculty of Medicine, Jagiellonian University, Medical College, Botaniczna 3, 31-503, Krakow, Poland.
Mol Neurobiol. 2016 Aug;53(6):4094-4125. doi: 10.1007/s12035-015-9337-5. Epub 2015 Jul 22.
The pathophysiologies of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD), are far from being fully explained. Oxidative stress (OS) has been proposed as one factor that plays a potential role in the pathogenesis of neurodegenerative disorders. Clinical and preclinical studies indicate that neurodegenerative diseases are characterized by higher levels of OS biomarkers and by lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review the current knowledge regarding the involvement of OS in neurodegenerative diseases, based on clinical trials and animal studies. In addition, we analyze the effects of the drug-induced modulation of oxidative balance, and we explore pharmacotherapeutic strategies for OS reduction.
包括肌萎缩侧索硬化症（ALS）、帕金森病（PD）和阿尔茨海默病（AD）在内的神经退行性疾病的病理生理学远未得到充分解释。氧化应激（OS）已被认为是在神经退行性疾病发病机制中发挥潜在作用的一个因素。临床和临床前研究表明，神经退行性疾病的特征是大脑和外周组织中OS生物标志物水平较高，而抗氧化防御生物标志物水平较低。在本文中，我们基于临床试验和动物研究，综述了关于OS参与神经退行性疾病的现有知识。此外，我们分析了药物诱导的氧化平衡调节的效果，并探讨了降低OS的药物治疗策略。
